Differential effects of phototherapy, adalimumab and betamethasone-calcipotriol on effector and regulatory T cells in psoriasis
Open Access
- 12 January 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 179 (1) , 127-135
Abstract
Background Psoriasis is a chronic T-cell-mediated skin disease with marked social and economic burdens. Current treatments are unsatisfactory, with unpredictable remission times and incompletely understood modes of action. Recent advances in our understanding of the pathogenesis of psoriasis have identified the imbalance between CD4+ T effector cells, particularly the T helper (Th)17 subset, and regulatory T cells (Tregs) as key to the development of psoriatic lesions, and therefore a novel therapeutic target. Objectives To quantify in patients the effects of three commonly used psoriasis treatment modalities on the Th1, Th2, Th17 and Treg subsets, and to test whether any change correlates with clinical response. Methods Flow cytometry was used to enumerate Th1, Th2, Th17 and Treg subsets in blood and skin of patients with psoriasis before and after receiving any of the following treatments: narrowband ultraviolet B (NB-UVB), adalimumab and topical betamethasone–calcipotriol combination (Dovobet®) Results All patients responded clinically to the treatments. NB-UVB significantly increased the numbers of circulating and skin Tregs, while, by contrast, adalimumab reduced Th17 cells in these compartments, and Dovobet had dual effects by both increasing Tregs and reducing Th17 cells. Conclusions The differential effects reported here for the above-mentioned treatment modalities could be exploited to optimize or design therapeutic strategies to overcome the inflammatory drivers more effectively and restore the Th17–Treg balance in psoriasis.Keywords
Funding Information
- The Egyptian Cultural Bureau Office
- Grampian NHS Endowments (RG12745)
This publication has 39 references indexed in Scilit:
- Photo(chemo)therapy Reduces Circulating Th17 Cells and Restores Circulating Regulatory T Cells in PsoriasisPLOS ONE, 2013
- Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammationJournal of Experimental Medicine, 2012
- Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in PsoriasisThe Journal of Immunology, 2011
- Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of PsoriasisPLOS ONE, 2010
- Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genesJournal of Allergy and Clinical Immunology, 2009
- Foxp3+ regulatory T cells maintain immune homeostasis in the skinJournal of Experimental Medicine, 2008
- Nitric oxide induces CD4+CD25+Foxp3−regulatory T cells from CD4+CD25−T cells via p53, IL-2, and OX40Proceedings of the National Academy of Sciences, 2007
- Vitamin D and autoimmunity: new aetiological and therapeutic considerationsAnnals of the Rheumatic Diseases, 2007
- Phenotypic and functional features of human Th17 cellsJournal of Experimental Medicine, 2007
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006